Bactiguard
Manufacturing · Sweden · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Alfred Nobels Alle 150, Stockholm, Stock...Phone Number
+46 84405880Website
www.bactiguard.comRevenue
$20.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Bactiguard
Bactiguard is a global MedTech company specializing in the development of safe and biocompatible technology aimed at preventing medical device-related infections. Their patented coating technology, based on an ultra-thin noble metal alloy, significantly reduces microbial adhesion and biofilm formation on medical devices, enhancing treatment outcomes. Bactiguard operates through license partnerships with leading MedTech companies, allowing them to integrate this technology into their products. Additionally, Bactiguard offers a range of wound care products, including HYDROCYN aqua, to support healing and infection prevention.Explore more
Bactiguard Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bactiguard your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Bactiguard launches new products
Congratulate Masked Content for being promoted to Masked Content at Bactiguard
Check if Bactiguard has recently received funding, and reach out quickly before it becomes old news!
Bactiguard, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Bactiguard recently announced quarterly report
Click to see if Bactiguard had a recent Job posting/layoffs
Check out if Bactiguard is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Bactiguard has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Bactiguard is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bactiguard is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bactiguard.
Bactiguard Tech Stack
A closer look at the technologies used by Bactiguard
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Bactiguard News & Media
Bactiguard Holding AB’s interim report third quarter 2024
Bactiguard delivers positive EBITDA and initiates review of 2028 financial targets due to previously announced agreement termination Third quarter 2024 (July – September) · Total revenue amounted to SEK 73.9 (49.5) million, an increase of SEK 24.5 million corresponding to 49.4%. · Net sales amounted to SEK 67.3 (45.5) million, an increase of SEK 21.9 million corresponding to 48.1%. Adjusted for currency effects of SEK -4.2 million, net sales increased by 57.5%. · Operating lossInvitation to presentation of Bactiguard’s interim report for the third quarter 2024
Bactiguard Holding AB (publ) publishes its interim report for the third quarter on Thursday 24 October 2024 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com (https://ir.bactiguard.com/report/q3-2024/). To participate in the audiocast, please use this link: ir.baZimmer Biomet terminates agreement for multiple orthopedic product segments – trauma agreement remains in effect
Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with the US Food and Drug Administration (FDA) than initially expected by Zimmer Biomet. There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impactBactiguard Holding AB’s interim report second quarter 2024
License revenues and EBITDA stabilizing Second quarter 2024 (April – June) · Total revenue amounted to SEK 60.9 (51.2) million, an increase of SEK 9.7 million corresponding to 18.9%. · Net sales amounted to SEK 57.4 (44.2) million, an increase of SEK 13.2 million corresponding to 29.8%. Adjusted for currency effects of SEK 0.2 million, net sales increased by 30.1%. · Operating loss amounted to SEK 10.8 (67.8) million.* · EBITDA amounted to SEK 1.2
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Bactiguard
Sign Up For FreeTo access detailed company insights
Bactiguard is a global MedTech company specializing in the development of safe and biocompatible technology aimed at preventing medical device-related infections. Their patented coating technology, based on an ultra-thin noble metal alloy, significantly reduces microbial adhesion and biofilm formation on medical devices, enhancing treatment outcome... Read More
